Rigel Pharmaceuticals' R289 Shows Promise for Treating Lower-Risk Myelodysplastic Syndrome

Rigel Pharmaceuticals Advances Treatment for Lower-Risk Myelodysplastic Syndrome with R289

Rigel Pharmaceuticals, Inc. has unveiled promising preliminary results from its ongoing Phase 1b study of R289, an oral prodrug of R835, aimed at addressing relapsed or refractory lower-risk myelodysplastic syndrome (MDS). Presented at the 67th American Society of Hematology Annual Meeting by Dr. Guillermo Garcia-Manero, the study highlights R289's potential to improve patient outcomes in a challenging demographic. With a focus on transfusion-dependent patients, the study reveals a red blood cell transfusion independence (RBC-TI) rate of 33% for those receiving doses of 500 mg once daily or higher, and an even more encouraging 40% for patients on a 500 mg twice-daily regimen.

The clinical trial involves a cohort of 33 patients, primarily elderly, with a median age of 75 years and a history of receiving multiple therapies—averaging three prior treatments. This patient population is notable for its complexity, as 76% had previously been treated with luspatercept, and 61% were identified with a high transfusion burden. This demographic highlights the need for innovative therapies, as these patients often face limited options. Notably, R289 is well tolerated, with the most common side effects being diarrhea and fatigue, reported by 30% and 27% of participants, respectively. This favorable safety profile may further enhance R289's attractiveness as a treatment alternative.

Dr. Lisa Rojkjaer, Chief Medical Officer at Rigel, underscores the urgent need for new therapies in the MDS space, particularly for patients who struggle to manage their condition despite previous treatments. The study aims to conclude its dose expansion phase by the second half of 2026, with plans to randomize up to 40 patients to establish the recommended Phase 2 dose. The median treatment duration of 5.5 months among participants suggests sustained engagement with R289, indicating its potential to offer significant benefits to this underserved patient population.

In addition to the promising data surrounding R289, Rigel Pharmaceuticals is positioned within a rapidly evolving biotechnology landscape that emphasizes targeted therapies for hematologic disorders and cancer. The company's commitment to developing innovative treatments aligns with the growing demand for effective therapies in this area, particularly as healthcare providers seek to address the complexities of diseases like MDS.

As Rigel moves forward with its clinical studies, the ongoing development of R289 represents a critical step toward improving care for patients with lower-risk MDS, a population often overlooked in hematologic research. The results from the Phase 1b study not only provide hope for patients but also reinforce Rigel's role as a key player in the biotechnology field, focused on hematologic disorders and cancer.